Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy

Roger BedimoInfectious Disease section, VA North Texas Health Care System, TX, USAAbstract: HIV-infected patients on highly active antiretroviral therapy (HAART) develop a complex of body composition changes known, including peripheral fat loss (lipoatrophy) and central fat accumulation (lipohypertr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Bedimo R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/077f68c999454baf9a932f0acba231b4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:077f68c999454baf9a932f0acba231b4
record_format	dspace
spelling	oai:doaj.org-article:077f68c999454baf9a932f0acba231b42021-12-02T05:55:22ZGrowth hormone and tesamorelin in the management of HIV-associated lipodystrophy1179-1373https://doaj.org/article/077f68c999454baf9a932f0acba231b42011-07-01T00:00:00Zhttp://www.dovepress.com/growth-hormone-and-tesamorelin-in-the-management-of-hiv-associated-lip-a7834https://doaj.org/toc/1179-1373Roger BedimoInfectious Disease section, VA North Texas Health Care System, TX, USAAbstract: HIV-infected patients on highly active antiretroviral therapy (HAART) develop a complex of body composition changes known, including peripheral fat loss (lipoatrophy) and central fat accumulation (lipohypertrophy). These changes may cause significant patient distress, which could in turn interfere with adherence to antiretroviral therapy. Treatment options &ndash; including antiretroviral switch, insulin sensitizers, and surgical approaches &ndash; have been associated with limited success and potential complications. The observation that low growth hormone levels are associated with central fat accumulation among HIV patients has led to the development of tesamorelin (a growth hormone releasing hormone analog) for the management of central fat accumulation. Randomized controlled trials have shown that administration of tesamorelin is safe and effective in reducing central fat accumulation among HIV-infected patients. This effect is transient, however, and its association with improved cardiovascular risk remains unclear.Keywords: HAART, HIV, tesamorelin, lipodystrophyBedimo RDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2011, Iss default, Pp 69-79 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Bedimo R Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
description	Roger BedimoInfectious Disease section, VA North Texas Health Care System, TX, USAAbstract: HIV-infected patients on highly active antiretroviral therapy (HAART) develop a complex of body composition changes known, including peripheral fat loss (lipoatrophy) and central fat accumulation (lipohypertrophy). These changes may cause significant patient distress, which could in turn interfere with adherence to antiretroviral therapy. Treatment options &ndash; including antiretroviral switch, insulin sensitizers, and surgical approaches &ndash; have been associated with limited success and potential complications. The observation that low growth hormone levels are associated with central fat accumulation among HIV patients has led to the development of tesamorelin (a growth hormone releasing hormone analog) for the management of central fat accumulation. Randomized controlled trials have shown that administration of tesamorelin is safe and effective in reducing central fat accumulation among HIV-infected patients. This effect is transient, however, and its association with improved cardiovascular risk remains unclear.Keywords: HAART, HIV, tesamorelin, lipodystrophy
format	article
author	Bedimo R
author_facet	Bedimo R
author_sort	Bedimo R
title	Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
title_short	Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
title_full	Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
title_fullStr	Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
title_full_unstemmed	Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
title_sort	growth hormone and tesamorelin in the management of hiv-associated lipodystrophy
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/077f68c999454baf9a932f0acba231b4
work_keys_str_mv	AT bedimor growthhormoneandtesamorelininthemanagementofhivassociatedlipodystrophy
_version_	1718400153639976960

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy

Ejemplares similares